betaxolol has been researched along with Glaucoma, Suspect in 46 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 9.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension." | 9.17 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. ( Chi, W; Li, A; Wang, S; Zhu, X, 2013) |
| "To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial." | 9.10 | Results of the betaxolol versus placebo treatment trial in ocular hypertension. ( Bunce, C; Franks, W; Garway-Heath, D; Hitchings, R; Kamal, D; O'Sullivan, F; Ruben, S; Viswanathan, A, 2003) |
| "This study investigated the effect of betaxolol, a beta 1 selective blocker, on the retinal circulation in 10 patients with ocular hypertension." | 9.07 | Effect of betaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study. ( Chen, HC; Gupta, A; Kohner, EM; Rassam, SM, 1994) |
| "Alpha-chymotrypsin-induced ocular hypertension in albino rabbits is widely used as an experimental model to screen potential antiglaucoma drugs." | 7.67 | Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: a comparative study. ( Andermann, G; de Burlet, G; Himber, J, 1989) |
| " The side effect profile of unoprostone appears to be comparable to other established IOP-lowering agents." | 6.70 | A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. ( Kapik, B; Mertz, B; Nordmann, JP; Schwenninger, C; Shams, N; Yannoulis, NC, 2002) |
| " The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0." | 6.68 | A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. ( Serle, JB, 1996) |
| "01) twelve hours after dosing at each observation times." | 6.67 | [Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension]. ( Demailly, P; Denis, P; Saraux, H, 1993) |
| "In a double masked randomised clinical trial, 38 eyes from 38 pseudophakic patients over 21 years of age who had significant posterior capsule opacification after phacoemulsification were randomly assigned to receive either betaxolol 0." | 5.51 | The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy. ( Elmi Sadr, N; Paknazar, F; Saber, E, 2022) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 5.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension." | 5.17 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. ( Chi, W; Li, A; Wang, S; Zhu, X, 2013) |
| "To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial." | 5.10 | Results of the betaxolol versus placebo treatment trial in ocular hypertension. ( Bunce, C; Franks, W; Garway-Heath, D; Hitchings, R; Kamal, D; O'Sullivan, F; Ruben, S; Viswanathan, A, 2003) |
| "At 1 year, the mean percent reduction in intraocular pressure at peak of 2% dorzolamide, 0." | 5.08 | A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. ( Strahlman, E; Tipping, R; Vogel, R, 1995) |
| "To assess the safety and intraocular pressure (IOP)-lowering activity of 2% dorzolamide (topical carbonic anhydrase inhibitor), compared to 0." | 5.08 | A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study. ( Ballantyne, C; Gray, TB; Simpson, AJ, 1996) |
| " In studies 1 and 2, there was a mean reduction in intraocular pressure from a betaxolol baseline of approximately 3 to 4 mmHg." | 5.08 | Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. ( Robin, AL, 1996) |
| "This study investigated the effect of betaxolol, a beta 1 selective blocker, on the retinal circulation in 10 patients with ocular hypertension." | 5.07 | Effect of betaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study. ( Chen, HC; Gupta, A; Kohner, EM; Rassam, SM, 1994) |
| "In a prospective, randomized study, nineteen patients with ocular hypertension (n = 14) or chronic open-angle glaucoma (n = 5) were treated with either betaxolol 0." | 5.07 | Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. ( Collignon-Brach, J, 1994) |
| "Betaxolol, a new beta 1-adrenergic blocker, was applied to 20 eyes of ten patients with ocular hypertension." | 5.05 | Effects of topical betaxolol in ocular hypertensive patients. ( Caldwell, DR; Guzek, JP; Salisbury, CR, 1984) |
| "5% and carteolol 2% on the blood flow velocity of the central retinal artery (CRA), the posterior ciliary artery (PCA) and the ophthalmic artery (OA) in patients with ocular hypertension." | 3.71 | Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. ( Belcaro, GV; Cesarone, MR; De Sanctis, MT; Incandela, L; Laurora, G; Minicucci, R; Steigerwalt, RD, 2001) |
| "Alpha-chymotrypsin-induced ocular hypertension in albino rabbits is widely used as an experimental model to screen potential antiglaucoma drugs." | 3.67 | Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: a comparative study. ( Andermann, G; de Burlet, G; Himber, J, 1989) |
| "5% twice daily in 39 patients with ocular hypertension or primary open-angle glaucoma already being treated with dipivefrin 0." | 3.67 | Effect of adding betaxolol to dipivefrin therapy. ( Kushner, FH; Ritch, R; Weinreb, RN, 1986) |
| "Four hundred sixteen subjects with ocular hypertension (intraocular pressure >/=22 and | 2.75 | The ability of short-wavelength automated perimetry to predict conversion to glaucoma. ( Colen, TP; Lemij, HG; Reus, NJ; van der Schoot, J, 2010) |
| " The side effect profile of unoprostone appears to be comparable to other established IOP-lowering agents." | 2.70 | A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. ( Kapik, B; Mertz, B; Nordmann, JP; Schwenninger, C; Shams, N; Yannoulis, NC, 2002) |
| " The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0." | 2.68 | A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. ( Serle, JB, 1996) |
| "01) twelve hours after dosing at each observation times." | 2.67 | [Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension]. ( Demailly, P; Denis, P; Saraux, H, 1993) |
| "Twenty-nine of these were treated for glaucoma and eight followed for ocular hypertension without treatment." | 1.30 | Five-year follow-up of treated patients with glaucoma using resolution perimetry. ( Martin, L; Wanger, P, 1998) |
| "In 35 of the 56 treated glaucoma patients the thresholds improved more than 0." | 1.29 | The effect of treatment on the results of high-pass resolution perimetry in glaucoma. ( Martin-Boglind, L; Wanger, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (19.57) | 18.7374 |
| 1990's | 22 (47.83) | 18.2507 |
| 2000's | 10 (21.74) | 29.6817 |
| 2010's | 3 (6.52) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Elmi Sadr, N | 1 |
| Saber, E | 1 |
| Paknazar, F | 1 |
| Harasymowycz, P | 1 |
| Royer, C | 1 |
| Cui, AX | 1 |
| Barbeau, M | 1 |
| Jobin-Gervais, K | 1 |
| Mathurin, K | 1 |
| Lachaine, J | 1 |
| Beauchemin, C | 1 |
| Chi, W | 1 |
| Li, A | 1 |
| Wang, S | 1 |
| Zhu, X | 1 |
| van der Schoot, J | 1 |
| Reus, NJ | 1 |
| Colen, TP | 1 |
| Lemij, HG | 1 |
| Rahman, MQ | 1 |
| Abeysinghe, SS | 1 |
| Kelly, S | 1 |
| Roskell, NS | 1 |
| Shannon, PR | 1 |
| Abdlseaed, AA | 1 |
| Montgomery, DM | 1 |
| Kamal, D | 1 |
| Garway-Heath, D | 1 |
| Ruben, S | 1 |
| O'Sullivan, F | 1 |
| Bunce, C | 1 |
| Viswanathan, A | 1 |
| Franks, W | 1 |
| Hitchings, R | 1 |
| Kałuzny, BJ | 1 |
| McCarey, BE | 1 |
| Kapik, BM | 1 |
| Kane, FE | 1 |
| Schröder, H | 1 |
| Bengtsson, B | 1 |
| Leske, MC | 1 |
| Hyman, L | 1 |
| Heijl, A | 1 |
| Smith, JP | 1 |
| Weeks, RH | 1 |
| Newland, EF | 1 |
| Ward, RL | 1 |
| Caldwell, DR | 2 |
| Salisbury, CR | 1 |
| Guzek, JP | 1 |
| Morsman, CD | 1 |
| Bosem, ME | 1 |
| Lusky, M | 1 |
| Weinreb, RN | 3 |
| Strahlman, E | 1 |
| Tipping, R | 1 |
| Vogel, R | 1 |
| Martin-Boglind, L | 1 |
| Wanger, P | 2 |
| Gupta, A | 1 |
| Chen, HC | 1 |
| Rassam, SM | 1 |
| Kohner, EM | 1 |
| Jain, S | 1 |
| Collignon-Brach, J | 2 |
| Frishman, WH | 1 |
| Fuksbrumer, MS | 1 |
| Tannenbaum, M | 1 |
| Vuori, ML | 1 |
| Ali-Melkkilä, T | 1 |
| Denis, P | 1 |
| Demailly, P | 2 |
| Saraux, H | 1 |
| Albracht, DC | 1 |
| LeBlanc, RP | 1 |
| Cruz, AM | 1 |
| Lamping, KA | 1 |
| Siegel, LI | 1 |
| Stern, KL | 1 |
| Kelley, EP | 1 |
| Stoecker, JF | 1 |
| Ananthanarayan, CR | 1 |
| Vaile, SJ | 1 |
| Feldman, F | 1 |
| Simpson, AJ | 1 |
| Gray, TB | 1 |
| Ballantyne, C | 1 |
| Serle, JB | 1 |
| Robin, AL | 1 |
| Gillies, WE | 2 |
| Brooks, AM | 2 |
| Greenfield, DS | 1 |
| Liebmann, JM | 1 |
| Ritch, R | 2 |
| Martin, L | 1 |
| Morrison, JC | 1 |
| Nylander, KB | 1 |
| Lauer, AK | 1 |
| Cepurna, WO | 1 |
| Johnson, E | 1 |
| Flammer, J | 1 |
| Graves, SA | 1 |
| Lass, JH | 1 |
| Khosrof, SA | 1 |
| Laurence, JK | 1 |
| Horwitz, B | 1 |
| Ghosh, K | 1 |
| Adamsons, I | 1 |
| Pattinson, TJ | 1 |
| Gibson, CR | 1 |
| Manuel, FK | 1 |
| Bishop, SL | 1 |
| March, WF | 1 |
| Javitt, J | 1 |
| Goldberg, I | 1 |
| Cantor, LB | 1 |
| Hoop, J | 1 |
| Katz, LJ | 1 |
| Flartey, K | 1 |
| Nordmann, JP | 1 |
| Mertz, B | 1 |
| Yannoulis, NC | 1 |
| Schwenninger, C | 1 |
| Kapik, B | 1 |
| Shams, N | 1 |
| Steigerwalt, RD | 1 |
| Laurora, G | 1 |
| Belcaro, GV | 1 |
| Cesarone, MR | 1 |
| De Sanctis, MT | 1 |
| Incandela, L | 1 |
| Minicucci, R | 1 |
| Stefan, C | 1 |
| Nenciu, A | 1 |
| Balaş, M | 1 |
| Neacşu, A | 1 |
| Lascu, L | 1 |
| Goode, SM | 1 |
| Horwitz, BL | 1 |
| Laibovitz, R | 1 |
| Shrader, CE | 1 |
| Stewart, RH | 1 |
| Williams, AT | 1 |
| Himber, J | 1 |
| de Burlet, G | 1 |
| Andermann, G | 1 |
| Clark, JB | 1 |
| Harper, CA | 1 |
| Mantzioros, N | 1 |
| Maas, S | 1 |
| Ros, FE | 1 |
| De Heer, LJ | 1 |
| De Keizer, RJ | 1 |
| Feghali, JG | 1 |
| Kaufman, PL | 1 |
| Nelson, WL | 1 |
| Kuritsky, JN | 1 |
| Long, DA | 1 |
| Johns, GE | 1 |
| Mullen, RS | 1 |
| Bowe, RG | 1 |
| Alexander, D | 1 |
| Epstein, DL | 1 |
| Weiss, MJ | 1 |
| Masi, RJ | 1 |
| Charap, AD | 1 |
| Eto, CY | 1 |
| Kushner, FH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation[NCT00705757] | Phase 4 | 89 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression - A Randomized Control Trial[NCT05940623] | 142 participants (Anticipated) | Interventional | 2023-08-24 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Periocular skin color was measured with the Minolta Chroma Meter CR-400 and the L*a*b* system, also known as Commission Internationale de l'Eclairage. This is a well-accepted unit of measurement in which L* corresponds to brightness and a* and b* correspond to chromaticity.~Measurements were taken at baseline and 1 year. Data from each time point and each location (upper and lower eyelids or cheeks/face) were averaged, and subtracted from the baseline value for that location. Six predetermined areas on and around the upper and lower eyelid and 2 areas of the face/cheek were measured.Upper and lower eyelid values were averaged and reported as single value for each location ie;-upper eyelids, lower eyelid and cheek/face. A decrease in luminance indicates increased pigmentation at the site of measurement." (NCT00705757)
Timeframe: one year
| Intervention | L*a*b* (Mean) | ||
|---|---|---|---|
| Upper Lid | Lower Lid | Cheek/Face | |
| Lumigan | -0.90 | -0.37 | 0.30 |
| Travatan | -0.90 | 0.17 | 0.51 |
| Xalatan | -1.42 | 0.48 | 0.55 |
3 reviews available for betaxolol and Glaucoma, Suspect
| Article | Year |
|---|---|
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Topics: Amides; Antihypertensive Agents; Bayes Theorem; Betaxolol; Bimatoprost; Brimonidine Tartrate; Carteo | 2022 |
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Humans; Levobu | 1994 |
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Clinical Tr | 1997 |
31 trials available for betaxolol and Glaucoma, Suspect
| Article | Year |
|---|---|
The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy.
Topics: Betaxolol; Brimonidine Tartrate; Capsule Opacification; Glaucoma; Humans; Intraocular Pressure; Lens | 2022 |
Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Topics: Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Drug Administration Schedule; Drug C | 2013 |
The ability of short-wavelength automated perimetry to predict conversion to glaucoma.
Topics: Aged; Antihypertensive Agents; Betaxolol; Double-Blind Method; Female; Follow-Up Studies; Glaucoma; | 2010 |
Results of the betaxolol versus placebo treatment trial in ocular hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Double-Blind Method; Female; Glaucoma; Humans; Intraoc | 2003 |
[Betaxolol for prevention of steroid induced intraocular pressure elevations in patients after radial keratotomy].
Topics: Adult; Betaxolol; Corneal Edema; Dexamethasone; Female; Humans; Keratotomy, Radial; Male; Middle Age | 2003 |
Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Dinoprost; Double-Blind Method; | 2004 |
Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Disease Prog | 2007 |
Betaxolol and acetazolamide. Combined ocular hypotensive effect.
Topics: Acetazolamide; Administration, Oral; Adult; Aged; Aqueous Humor; Betaxolol; Clinical Trials as Topic | 1984 |
Effects of topical betaxolol in ocular hypertensive patients.
Topics: Administration, Topical; Betaxolol; Humans; Ocular Hypertension; Propanolamines | 1984 |
The effect of topical beta-adrenoceptor blocking agents on pulsatile ocular blood flow.
Topics: Adrenergic beta-Antagonists; Betaxolol; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Press | 1995 |
A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betaxolol; Carbonic Anhydrase I | 1995 |
Effect of betaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study.
Topics: Administration, Topical; Betaxolol; Blood Flow Velocity; Humans; Intraocular Pressure; Ocular Hypert | 1994 |
Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma.
Topics: Administration, Topical; Adult; Aged; Betaxolol; Chronic Disease; Female; Glaucoma, Open-Angle; Huma | 1994 |
The effect of betaxolol and timolol on postoperative intraocular pressure.
Topics: Betaxolol; Cataract Extraction; Double-Blind Method; Humans; Intraocular Pressure; Lenses, Intraocul | 1993 |
[Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension].
Topics: Adult; Benzalkonium Compounds; Betaxolol; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; | 1993 |
A double-masked comparison of betaxolol and dipivefrin for the treatment of increased intraocular pressure.
Topics: Aged; Betaxolol; Double-Blind Method; Epinephrine; Female; Glaucoma, Open-Angle; Heart Rate; Humans; | 1993 |
A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Carbonic Anhydrase Inhibitor | 1996 |
A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; B | 1996 |
Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Double-Blind Method; Drug Therapy, Combination; Female | 1996 |
A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Australia; Bet | 1996 |
A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Carbonic Anhydrase Inhibitor | 1998 |
The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Adult; Betaxolol; Double-Blind Method; Human | 1999 |
Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; B | 2000 |
Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Female; Hum | 2001 |
A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Dinoprost; Double-Blind Method; Exf | 2002 |
[Non surgical alternatives in the treatment of the primitive open angle glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Glauco | 2001 |
A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.
Topics: Administration, Topical; Analysis of Variance; Betaxolol; Dose-Response Relationship, Drug; Double-B | 1990 |
A comparison of the efficacy of betaxolol and timolol in ocular hypertension with or without adrenaline.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Clinical Trials as Topic; Double-Bl | 1989 |
Efficacy and safety of the combination therapy Pilogel/beta-blocker: interim results.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Circadian Rhythm; Clinical Trials as Topic; Drug Thera | 1989 |
Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Female; Humans; Intraocular Pressure; Male; Mid | 1985 |
Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure.
Topics: Betaxolol; Clinical Trials as Topic; Double-Blind Method; Glaucoma; Humans; Intraocular Pressure; Le | 1988 |
12 other studies available for betaxolol and Glaucoma, Suspect
| Article | Year |
|---|---|
Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database.
Topics: Algorithms; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Clinical Protocols; Databases, | 2011 |
[Increased intraocular pressure in asthma patients].
Topics: Adrenergic beta-Agonists; Anti-Asthmatic Agents; Asthma; Betaxolol; Glaucoma; Glucocorticoids; Human | 2005 |
The effect of treatment on the results of high-pass resolution perimetry in glaucoma.
Topics: Aged; Betaxolol; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Male; Ocula | 1994 |
Betaxolol-associated anterior uveitis.
Topics: Aged; Betaxolol; Female; Humans; Ocular Hypertension; Uveitis, Anterior | 1994 |
Acute episode of asthma following topical administration of betaxolol eyedrops.
Topics: Acute Disease; Aged; Aged, 80 and over; Asthma; Betaxolol; Cataract Extraction; Female; Humans; Ocul | 1993 |
Five-year follow-up of treated patients with glaucoma using resolution perimetry.
Topics: Aged; Betaxolol; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular | 1998 |
Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Clonidine; Disease Model | 1998 |
[A long-term study of the visual fields in patients treated with betaxolol and timolol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Belgium; Betaxolol; Female; Glaucoma; Glaucoma, Angle-Clos | 1998 |
Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol.
Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Betaxolol; Blood Flow Velocity; Carte | 2001 |
Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: a comparative study.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Chymotrypsin; Clonidine; Ocular Hypertension; Pigme | 1989 |
Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans; Ocular Hypertension; Product Surveillance, | 1987 |
Effect of adding betaxolol to dipivefrin therapy.
Topics: Aged; Betaxolol; Drug Therapy, Combination; Epinephrine; Female; Glaucoma, Open-Angle; Humans; Male; | 1986 |